MediWound: A $24 Million Promise Meets an Unfunded Factory
Guidance now rests on a U.S. government check management admits may never arrive — and the VALUE readout has quietly slid to mid-2027.
MDWD · Earnings Call · 2026-11-12
The guidance that quietly stopped being guidance
For two consecutive quarters, MediWound's management repeated the same reassuring sentence about its $24 million to $26 million 2026 revenue target. In August, CFO Hani Luxenburg was emphatic that the facility delay did not matter: “we do not actually expect the current facility timeline to have material impact on our 2026 revenue guidance. Importantly, a meaningful portion of the revenue we expect in the second half is associated, as you know, with government-funded development activity and product supply under existing agreements rather than being depending on commercial supply from our expanded facility.” — Hani Luxenburg, CFO · 2026-08-13 On this call, that construction collapsed. The same guidance is now explicitly contingent on money nobody has committed. “A substantial portion of our anticipated 2026 revenue is tied to development services for this project. We do not yet know when or whether funding will be secured.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 And when pressed for the split on the Q&A, CEO Ofer Gonen declined to provide it: “it's a significant part of the $24 million to $26 million guidance. We are not prepared now to say how we break out this component of the guidance only to share that the substantial portion is tied to development services for the planned U.S.-based facility.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 That is the story of this quarter. lower revenue from development services is the company's own name for the problem — it entered the keyword set at a high rank this quarter, and it describes a 9-month revenue line of $8.1 million against $15.1 million a year earlier. To hit the bottom of the range, MediWound would need roughly $16 million to $18 million in Q4 alone, against $8.1 million across the preceding nine months. The U.S. government is not a backdrop here; it is the P&L.The key uncertainty, and we highlighted this is the U.S.-based manufacturing facility. We are still in ongoing discussions with them, all kinds of funding discussions that I cannot get into details now, and I don't know when it will be secured.